Gerardo Ferbeyre, a research member at the Institute, and Sebastian Igelmann, a doctoral student in his laboratory and first author of the study, have made a discovery that opens a new avenue for potential cancer therapies. The two scientists published a study in Molecular Cell showing that an enzyme complex called HTC (hydride transfer complex) can inhibit cell aging.

When cells age, a state called “cellular senescence” occurs and cells stop dividing. HTC, composed of three enzymes, may be a potential target for stopping the growth of cancer cells in certain types of cancer, including prostate cancer.

To read the full story, click here.